Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of LY3549492 Compared With Placebo in Adult Participants Aged 55 to 80 Years With a BMI of 22 to 25 kg/m2

NCT07085468 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07085468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07085468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of LY3549492 Compared With Placebo in Adult Participants Aged 55 to 80 Years With a BMI of 22 to 25 kg/m2
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
July 21, 2025
Completion date
August 14, 2025
Enrollment
1 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

healthy